News

Confo Therapeutics expands board with appointment of Rob Scott as Independent Director

Details

Confo Therapeutics today announced the appointment of Rob Scott as an Independent Director. Dr. Scott’s career spans 30 years of drug discovery and development leadership in the global pharmaceutical and biotechnology industries, including his last position as Chief Medical Officer, Head of Development at AbbVie.

GTX Medical was granted FDA Breakthrough Device Designation for Go-2 Targeted Epidural Spinal Stimulation (TESS) system

Details

The US Food and Drug Administration has granted Breakthrough Device Designation for GTX Medical‘s implantable Go-2 system which was designed to promote the recovery of leg motor functions and neurological control in adults with spinal cord injuries (SCI) and paralysis. The Go-2 System provides Targeted Epidural Spinal Stimulation (TESS) therapy, promoting the recovery of leg motor functions and neurological control. The Company anticipates the first clinical trial for the complete Go-2 system in humans to take place in 2021. 

Confo Therapeutics appoints Paolo Vicini as Chief Development Officer

Details

Confo Therapeutics today announced the appointment of Paolo Vicini in the newly-created position of CDO effective June 1, 2020.With two decades of leadership and scientific experience in pharmaceutical research and development, Dr. Vicini will apply his experience in translational and clinical sciences to support the Company as it moves its GPCR modulating small molecules through preclinical studies and into the clinic.

  1. Wellington Partners’s portfolio company Themis to be acquired by MSD
  2. Themis collaborates with ABL Europe to manufacture its SARS-CoV-2 Vaccine Candidate in France
  3. UroMems appoints medical device industry leader Steffen Hovard to Board of Directors
  4. GTX Medical appoints John Murphy as Chief Technology Officer
© Wellington Partners, 2020.